Plasma lipids and lipoprotein reference values, and the prevalence of
dyslipoproteinemia in Canadian adults.
High-density lipoprotein deficiency and
dyslipoproteinemia associated with venous thrombosis in men.
This edition has new and updated coverage of the chemical basis for analyte assays and common interferences, lipids and
dyslipoproteinemia, markers in the blood for cardiac injury evaluation and related stroke disorders, among other additions.
Enhanced oxidative stress and
dyslipoproteinemia have been proposed as significant factors contributing to the accelerated development of macrovascular complications in diabetes," Dr.
An evaluation of the marmoset Callithrix jacchus (sagui) as an experimental model for the
dyslipoproteinemia of human Schistosomiasis mansoni.
Dwyer and Blizzard (1996), collected data on variables associated with
dyslipoproteinemia, hypertension, BMI and skinfold thickness in a group (n = 1834) of 9 and 15 year old children.
Hypertriglyceridemic hyperapo B: the unappreciated atherogenic
dyslipoproteinemia in type 2 diabetes mellitus.
It has been designed to measure the prevalence of risk factors including
dyslipoproteinemia, hyperglycemia, obesity, smoking, and hypertension.
Patent Number 6,673,780, entitled "Sulfoxide and Bis-sulfoxide Compounds and Compositions for Cholesterol Management and Related Uses," covers novel chemical compounds, pharmaceutical compositions comprising the compounds and methods for their use in the treatment of a variety of diseases, such as cardiovascular diseases, dyslipidemia,
dyslipoproteinemia and hypertension, and was invented by Esperion scientists.
The first comprehensive classification of
dyslipoproteinemia, formulated in the mid 1960s and adopted by the World Health Organization (WHO), described hyperlipoproteinemia as plasma phenotypes.
Hypertriglyceridemia, being associated with hepatic steatosis and oversecretion of large triglyceride-rich VLDL, is central to the pathophysiology of
dyslipoproteinemia in type 2 diabetes (7).
Patent Number 6,506,799, titled "Methods of treating cardiovascular diseases, dyslipidemia,
dyslipoproteinemia, and hypertension with ether compounds," covers methods for the use of certain small molecules to treat a variety of cardiovascular diseases and was invented by Esperion scientists.
